Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Marinos C. Dalakas, Allen Jr. Aksamit, David L. Madden, John L. Sever

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

Original languageEnglish (US)
Pages (from-to)933-935
Number of pages3
JournalArchives of Neurology
Volume43
Issue number9
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Amyotrophic Lateral Sclerosis
Interferon-alpha
Motor Neuron Disease
Interferons
Therapeutics

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis. / Dalakas, Marinos C.; Aksamit, Allen Jr.; Madden, David L.; Sever, John L.

In: Archives of Neurology, Vol. 43, No. 9, 01.01.1986, p. 933-935.

Research output: Contribution to journalArticle

Dalakas, Marinos C. ; Aksamit, Allen Jr. ; Madden, David L. ; Sever, John L. / Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis. In: Archives of Neurology. 1986 ; Vol. 43, No. 9. pp. 933-935.
@article{e201d407246d463f9568b05569daee7f,
title = "Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis",
abstract = "Recombinant leukocyte α2-interferon (with >98{\%} purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.",
author = "Dalakas, {Marinos C.} and Aksamit, {Allen Jr.} and Madden, {David L.} and Sever, {John L.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1001/archneur.1986.00520090061018",
language = "English (US)",
volume = "43",
pages = "933--935",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

AU - Dalakas, Marinos C.

AU - Aksamit, Allen Jr.

AU - Madden, David L.

AU - Sever, John L.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

AB - Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022482174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022482174&partnerID=8YFLogxK

U2 - 10.1001/archneur.1986.00520090061018

DO - 10.1001/archneur.1986.00520090061018

M3 - Article

C2 - 3741210

AN - SCOPUS:0022482174

VL - 43

SP - 933

EP - 935

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -